Compare Dover Corp (DOV) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs GeneDx Holdings Corp — how do they compare? Dover Corp trades at $189.69 (market cap $25.45B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Dover Corp is far larger — about 12.6× GeneDx Holdings Corp's market cap, and Dover Corp pays a 1.11% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and GeneDx Holdings Corp for 19 Days on average.
| DOV | WGS | |
|---|---|---|
Market Cap | $25.45B | $2.02B |
Volume | 661,758 | 734,640 |
Sector | Industrials | Health |
52-Week High | $233.31 | $167.51 |
52-Week Low | $161.16 | $34.51 |
Typical Hold Time | 73 Days | 19 Days |
Enterprise Value | $26.95B | $2.05B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOV trades at $189.32, up 0.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 results pending. Revenue for 2025 was $8.09B, with a net income margin of 13.48%, while analyst consensus is strongly positive with a $243.20 price target. Recent news highlights product launches and strategic acquisitions, such as the completion of the Cloeren acquisition in August 2026.
DOV presents a favorable fundamental outlook with solid profitability and analyst support, though technical indicators suggest near-term caution. Upside potential exists from earnings momentum and dividend reliability, but risks include market volatility and execution challenges from recent acquisitions. The stock's current price is below the consensus target, indicating room for growth if quarterly results meet expectations.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
